Journals / Retina-Vitreus / 2008 / Cilt: 16 - Sayı: 4

Intravitreal bevacizumab ınjection in submacular choroidal neovascularization due to angioid streaks

Angioid streak’e bağlı submaküler koroid neovaskülarizasyonunda intravitreal bevacizumab injeksiyonu

Pages
278–281
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further study with longer follow-up and large series is warranted to assess the long term efficacy and safety of IVB in this population.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of this study is to evaluate the results of intravitreal bevacizumab (IVB) treatment in patients with submacular choroidal neovascularization (CNV) due to angioid streaks (AS).
📊
Key Findings & Data:Materials and Methods: Six eyes of 6 patients with CNV due to AS were enrolled.
💡
Conclusion & Impact:Further study with longer follow-up and large series is warranted to assess the long term efficacy and safety of IVB in this population.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Tomografi · optik koherens · Anjiyoid çatlak

Abstract

Purpose: The aim of this study is to evaluate the results of intravitreal bevacizumab (IVB) treatment in patients with submacular choroidal neovascularization (CNV) due to angioid streaks (AS). Materials and Methods: Six eyes of 6 patients with CNV due to AS were enrolled. Visual acuity testing, systemic ophthalmologic examination, fluorescein angiography (FA) and optical coherence tomography (OCT) were used to evaluate the results of IVB treatment 2.5 mg/0.1 ml. Follow up examination were scheduled at each month and retreatments were considered when leakage was observed at FA and subretinal fluid observed in OCT. Results: Mean follow-up time was 6.6 months, during which eyes received an average of 3 injections. The baseline visual acuity was a mean of 0.36 logMAR and improved to 0.30 logMAR at the last visit. By the last follow-up there were 1 line increased in visual acuity in 2 patients (33%) and 2 lines in 3 patients (50%). One patient (16%) had the same visual acuity at the last follow-up. During follow-up no systemic or local complications were noted. Conclusions: Our short-term results in 6 patients support the use of IVB for the management of CNV in patients with AS. Further study with longer follow-up and large series is warranted to assess the long term efficacy and safety of IVB in this population.

Özet

Amaç: Bu çalışmanın amacı anjioid streak (AS) sonucu gelişen submaküler koroid neovaskülarizasyonlarında (KNV) uygulanan intravitreal bevacizumab (İVB) enjeksiyonunun sonuçlarını değerlendirmektir. Gereç ve Yöntem: AS sonucu gelişen KNV’si olan 6 olgunun 6 gözü değerlendirildi. İVB (2.5 mg/0.1 ml) tedavi sonuçları değerlendirilirken olguların görme keskinliği ve sistemik oftalmolojik muayeneleri yapıldı; fundus flöresein anjiografileri (FFA) ve optik koherens tomografileri (OKT) çekildi. Tedavi sonrası olgular birer ay aralar ile takip edildi ve FFA’da sızıntı gözlenen ve OKT’de retina altı sıvı tespit edilen olgulara tekrar tedavi uygulandı. Bulgular: Ortalama takip süresi 6.6 aydı ve bu süre içinde ortalama 3 enjeksiyon uygulandı. 0.36 logMAR olan başlangıç ortalama görme keskinliği son kontrolde 0.30 logMAR’a yükseldi. Son kontrollerde 2 hastada (%33) 1 sıra ve 3 hastada (%50) 2 sıra görme keskinliği artışı oldu. Bir olguda (%16) ise son kontrolde görme keskinliği aynı seviyede kaldı. Takip süresinde sistemik ya da lokal komplikasyona rastlanmadı. Sonuç: Altı hastayı kapsayan bu kısa dönem çalışmamız AS nedeniyle gelişen KNV’lerin tedavisinde İVB enjeksiyonunu desteklemektedir. Bu hasta grubunda İVB’nin uzun dönem etkinliği ve güvenirliğini tespit etmek için daha uzun takip süreli geniş çalışma serilerine ihtiyaç vardır.

🔖

Cite This Article

ŞENTÜRK, F., ÖZDEMİR, H., KARAÇORLU, A. S., KARAÇORLU, M. (2008). Intravitreal bevacizumab ınjection in submacular choroidal neovascularization due to angioid streaks. Retina-Vitreus, Cilt: 16 - Sayı: 4, 278–281. https://ajindex.com/articles/305197

References (14)

  1. Doyne R.: Choroidal and retinal changes, the results of flows on the eye. Trans Ophthalmol Soc UK. 1889;9:128
  2. Clarkson JG, Altman RD.: Angioid streaks. Surv Ophthalmol.1982;26:235-246
  3. Gass JDM. Angioid streaks. In: Stereoscopic Atlas of Macular Diseases. St. Louis: Mosby. 1997:118-123
  4. Schilling GS, Blach RK.: Prognosis and therapy of angioid streaks. Trans Ophthalmol Soc UK. 1975;95:301-305
  5. Geliksen O, Hendrikse F, Deutman AF.: A long-term follow-up study of laser coagulation of neovascular membranes in angioid streaks. Am J Ophthalmol. 1988;105:299-303
  6. Lim JI, Bressler NM, Marsh MJ, Bressler SB.: Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol. 1993;116:414-423
  7. Jurklies B, Bornfeld N, Schilling H.: Photodynamic therapy using verteporfin for choroidal neovascularization associated with angioid streaks-long-term effects. Ophthalmic Res. 2006;38:209-217
  8. Karacorlu M, Karacorlu S, Ozdemir H, et al.: Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol. 2002;134:360-366
  9. Roth DB, Estafanous M, Lewis H.: Macular translocation for subfoveal choroidal neovascularization in angioid streaks. Am J Ophthalmol. 2001;131:390-392
  10. Rosenfeld PJ, Moshfegni AA, Puliafito CA.: Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Laser Imaging. 2005;36:331-335
  11. Avery RL, Pieramici DJ, Rabena MD, et al.: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363-372
  12. Bhatnagar P, Freund KB, Spaide RF, et al.: Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. Retina. 2007;27:897-902
  13. Lommeatzsch A, Spital G, Trieshmann M, et al.: Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks. Ophthalmologe.2007;104:325-328
  14. Sachdev N, Vishwanathan K, Gupta V, et al.: Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks. Indian J Ophthalmol. 2007;55:457-458.